Patient Outcomes Linked To Biomarker Levels

JonN writes to tell us Science Daily is reporting that researchers at Yale University have discovered that current pathology methods for biomarker detection can be dramatically altered depending on the concentration of antibodies used. From the article: "Biomarkers may have the power to provide diagnostic, therapeutic, and prognostic information for personalized medicine." said Donald Earl Henson, M.D., of the George Washington University Cancer Institute, in "Back to the Drawing Board on Immunohistochemistry and Predictive Factors," an accompanying editorial. "However, immunohistochemistry, a popular technique for evaluating biomarker expression, may contain procedural flaws that jeopardize its promise."

Comments

Re:Computational Molecular Phenotyping

[0-9a-f]

[[ Offtopic, Meta-comment ]]

You know you've got a jaundiced view on life when you read an interested researcher's real science comments, and instinctively feel disgusted by the blatant PR grab.

On re-reading the parent comment, I almost feel obliged to visit the web site, to prove to myself that not everyone's just after the PR, but might actually have something relevant to say.

It's been a tough few weeks for SlashDot readers, full of front-page advertorials. Now the editorial sloppiness is causing me to doubt even "Score: 5, Informative" comments.

Thanks.